

# European Respiratory Society Annual Congress 2012

**Abstract Number:** 3502

**Publication Number:** 3074

**Abstract Group:** 11.2. Pleural and Mediastinal Malignancies

**Keyword 1:** Pleura **Keyword 2:** Palliative care **Keyword 3:** Lung cancer / Oncology

**Title:** The second therapeutic intervention in malignant effusion trial (TIME2): A randomised controlled trial to assess the efficacy and safety of patient controlled malignant pleural effusion drainage by indwelling pleural catheter compared to chest drain and talc slurry pleurodesis

Dr. Eleanor 25859 Mishra [eleanor.mishra@gmail.com](mailto:eleanor.mishra@gmail.com) MD <sup>1</sup>, Dr. Helen 25860 Davies [hedavies@doctors.org.uk](mailto:hedavies@doctors.org.uk) MD <sup>2</sup>, Dr. John 25861 Wrightson [john@wrightsons.net](mailto:john@wrightsons.net) MD <sup>1</sup>, Dr. Andrew 25862 Stanton [Andrew.Stanton@gwh.nhs.uk](mailto:Andrew.Stanton@gwh.nhs.uk) MD <sup>3</sup>, Dr. Anur 25863 Guhan [Anur.guhan@stees.nhs.uk](mailto:Anur.guhan@stees.nhs.uk) MD <sup>4</sup>, Dr. Christopher 25880 Davies [Chris.Davies@royalberkshire.nhs.uk](mailto:Chris.Davies@royalberkshire.nhs.uk) MD <sup>5</sup>, Dr. Jamal 25881 Grayez [jamal.grayez@ouh.nhs.uk](mailto:jamal.grayez@ouh.nhs.uk) MD <sup>6</sup>, Dr. Richard 25888 Harrison [RichardNeil.Harrison@nth.nhs.uk](mailto:RichardNeil.Harrison@nth.nhs.uk) MD <sup>7</sup>, Dr. Anjani 25899 Prasad [anjani.prasad@buckshosp.nhs.uk](mailto:anjani.prasad@buckshosp.nhs.uk) MD <sup>8</sup>, Ms. Nicky 25903 Crosthwaite [nicky.crosthwaite@orh.nhs.uk](mailto:nicky.crosthwaite@orh.nhs.uk) <sup>1</sup>, Prof. Y.C. Gary 25907 Lee [glee@meddent.uwa.edu.au](mailto:glee@meddent.uwa.edu.au) MD <sup>9</sup>, Dr. Robert 25924 Miller [RMiller@gum.ucl.ac.uk](mailto:RMiller@gum.ucl.ac.uk) MD <sup>10</sup>, Mr. Brennan 25933 Kahan [B.Kahan@ctu.mrc.ac.uk](mailto:B.Kahan@ctu.mrc.ac.uk) <sup>11</sup> and Dr. Najib 25936 Rahman [naj\\_rahman@yahoo.co.uk](mailto:naj_rahman@yahoo.co.uk) MD <sup>1</sup>. <sup>1</sup> Oxford Respiratory Trials Unit, University of Oxford, Oxfordshire, United Kingdom ; <sup>2</sup> Department of Respiratory Medicine, University Hospital of Wales, Cardiff, United Kingdom ; <sup>3</sup> Department of Respiratory Medicine, Great Western Hospital, Swindon, United Kingdom ; <sup>4</sup> Department of Respiratory Medicine, James Cook University Hospital, South Tees, United Kingdom ; <sup>5</sup> Department of Respiratory Medicine, Royal Berkshire Hospital, Reading, United Kingdom ; <sup>6</sup> Department of Respiratory Medicine, Horton Hospital, Banbury, United Kingdom ; <sup>7</sup> Department of Respiratory Medicine, University Hospital, North Tees, United Kingdom ; <sup>8</sup> Department of Respiratory Medicine, Buckinghamshire Hospitals NHS Trust, High Wycombe, United Kingdom ; <sup>9</sup> Department of Respiratory Medicine, University of Western Australia, Perth, Australia ; <sup>10</sup> Department of Genitourinary Medicine, University College London, United Kingdom and <sup>11</sup> Department of Statistics, Medical Research Council, London, United Kingdom .

**Body:** Introduction: Malignant pleural effusions (MPEs) can be treated by indwelling pleural catheter (IPC) or chest drain and talc pleurodesis (usual care). This is the first direct, randomised comparison of these techniques as initial therapy assessing patient reported outcomes. Methods: Randomised trial of IPC versus usual care (1:1) in patients with symptomatic MPE. IPCs were inserted as day cases, followed by patient education and home drainage. Usual care was admission for chest drain and talc pleurodesis in patients with good lung re-expansion. The primary outcomes were daily visual analogue scale (VAS) scores of breathlessness and chest pain over 42 days (100mm line, 0mm = no breathlessness/chest pain, 100mm = maximum breathlessness/pain). Results: 106 patients were randomised. Dyspnoea improved in both arms, with no significant difference in intensity (mean VAS: IPC 24.7mm (SD 18.9), usual care 24.4mm (SD 17.0), difference 0.16mm, 95% CI -6.82 to 7.15, p=0.96). Dyspnoea decreased by mean 37mm (SD 27.1) IPC arm and 30.2mm (SD 27.7) usual care arm. Chest pain decreased from baseline in both arms (mean VAS: IPC

20.5mm (SD 18.2), usual care 17.6mm (SD 16.0), difference 5.4mm, 95% CI -3.0 to 13.8,  $p=0.21$ ).

Preliminary analysis demonstrated lower initial hospital stay in the IPC group (median days 0 (IQR 0-1) versus 4 (IQR 2-6)). Discussion: IPC and usual care are comparably effective treatments for the relief of breathlessness in patients with MPE. The pain profile of IPC and usual care is similar over 6 weeks.